Table 3. Summary of the epitope coverage and binding affinities of 31 anti-PD-1 mAbs.
(KD values represent the mean values from 8–12 spots per mAb, as determined on the LSA using a CMD-P chip; ND = not determined; kd-limited in SPR capture-based assay in bold). Data for mAb33 and mAb34 were determined in a separate experiment. The mAbs are sorted by Bin. (see Fig 5).
| mAb ID | Analog of indicated INN | LSA KD (nM) | Bin | Blocks PD-L1 | Binds P35-Q167 PD-1 fragment | Shows mAb Displacement | Displaced mAbs |
|---|---|---|---|---|---|---|---|
| mAb22 | nivolumab | 7.2 | A* | Y | N | N | |
| mAb18 | <0.2 | A* | Y | N | N | ||
| mAb04 | retifanlimab | 0.7 | A | Y | Y | N | |
| mAb06 | 0.3 | A | Y | Y | N | ||
| mAb08 | 12 | A | Y | Y | N | ||
| mAb09 | <3.2 | A | Y | Y | N | ||
| mAb10 | 9.5 | A | Y | Y | N | ||
| mAb11 | 308 | A | Y | Y | N | ||
| mAb15 | balstilimab | 12 | A | Y | Y | N | |
| mAb16 | dostarlimab | 1.6 | A | Y | Y | N | |
| mAb17 | camrelizumab | 4 | A | Y | Y | N | |
| mAb20 | <0.1 | A | Y | Y | N | ||
| mAb21 | sintilimab | <0.1 | A | Y | Y | N | |
| mAb23 | cemiplimab | 1.5 | A | Y | Y | N | |
| mAb24 | ND | A | Y | Y | N | ||
| mAb25 | 424 | A | Y | Y | N | ||
| mAb28 | <0.2 | A | Y | Y | N | ||
| mAb29 | 3.2 | A | Y | Y | N | ||
| mAb31 | 1.6 | A | Y | Y | N | ||
| mAb33 | 6 | A | ND | ND | ND | ||
| mAb34 | <0.59 | A | ND | ND | ND | ||
| mAb14 | 136 | B | Y | N | Y | mAb02, 19 | |
| mAb02 | 67 | C | Y | Y | Y | mAb14, 26 | |
| mAb03 | tislelizumab | <0.1 | C | Y | Y | Y | mAb32 |
| mAb19 | sasanlimab | <0.2 | C | Y | Y | Y | mAb14, 26 |
| mAb05 | 3.1 | D | N | Y | N | ||
| mAb07 | 52 | E | Y | Y | Y | mAb27 | |
| mAb26 | 2.5 | F | Y | Y | Y | mAb02, 13, 19 | |
| mAb32 | 1.9 | F | Y | Y | Y | mAb03, 13, 27 | |
| mAb27 | 2.4 | G | Y | W# | Y | mAb07, 13, 32 | |
| mAb30 | 1 | H | N | Y | N | ||
| mAb12 | 9.2 | I | N | Y | N | ||
| mAb13 | pembrolizumab | 4 | J | Y | Y | Y | mab26, 27, 32 |
# Indicates weaker binding to N-terminal deleted PD-1.